New data from an AI-driven re-analysis of the SEANCON trial suggests the drug may provide benefits in more severe stroke cases.
The Australian phase 2 SEANCON clinical trial of the neuroprotective drug ARG-007 in acute ischemic stroke was presented at the 2026 European Stroke Organisation Conference (ESOC) in the Netherlands.
Trial Design and Primary Results
The SEANCON trial was a randomized, double-blind, placebo-controlled study conducted in 10 Australian hospitals. It involved 93 stroke patients undergoing endovascular thrombectomy (EVT). Professor Graeme Hankey AO, Perron Institute Chair in Stroke Research at The University of Western Australia, presented the findings.
The study found no statistically significant difference between the ARG-007 and placebo groups in the volume of infarcted brain tissue at three days follow-up. The study was not powered to reliably identify or exclude a statistically significant effect.
Pre-Specified and Post-Hoc Analyses
A pre-specified subgroup analysis generated the hypothesis that ARG-007 may reduce infarct volume in patients with slow collateral blood supply.
A poster by Dr. Davide Carone (Brainomix) reported a post-hoc AI core lab analysis, which the conference recognized as a Best Poster Finalist.
The AI-enabled analysis, approved by the United States Food and Drug Administration, classified trial participants based on initial stroke severity.
The analysis found that patients with larger strokes randomized to ARG-007 had statistically significant better functional outcomes and significantly lower follow-up volumes of brain tissue death compared to placebo.
Drug Development Background
ARG-007 is based on the work of Professor Bruno Meloni and Clinical Professor Neville Knuckey (University of Western Australia and Perron Institute) and is being commercialized by Argenica Therapeutics.
Dr. Liz Dallimore, Argenica's Managing Director, stated that reduced brain tissue death signifies neuroprotection and validates ARG-007's mechanism of action.
Next Steps
A Phase 2B clinical trial is planned, targeting moderate to severe stroke patients who may be most likely to benefit.
Dr. Dallimore indicated that severe acute ischemic stroke patients represent a high unmet medical need, often experiencing poorer outcomes following thrombectomy. She suggested that ARG-007's demonstrated efficacy for these patients indicates its potential as an adjunctive neuroprotective therapy for this group.